---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-023128"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-07-22T23:59:59+00:00"
generated_at: "2026-05-31T18:25:25.772914+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences Executive Chairman outlines Phase 3 trial timelines and transparency pledge

## Summary
- First Phase 3 simufilam trial (804 patients) to read out by Dec 2024; second by June 2025.
- Rick Barry takes roles of Executive Chairman and principal executive officer until new CEO.
- Company commits to rigorous science and timely disclosure of material news, good or bad.
- Trial data held by Premier Research; biostatistics by Pentara – Cassava won't see results early.

## SEC filing metadata
- accession: 0001437749-24-023128
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-07-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774924023128/0001437749-24-023128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774924023128/sava20240721_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-023128
- JSON: https://secwatch.observer/filing/0001437749-24-023128.json
- Plain text: https://secwatch.observer/filing/0001437749-24-023128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.